A complete application in a minute
Tailored resume and cover letter, ready to send.
Zealand Pharma A/S is seeking an Analytical Scientist on a 12-month maternity cover to support late-stage analytical development across Development and Life Cycle Management projects. You will work with CDMOs and internal teams, gaining hands-on experience in analytical work and regulatory documentation.
The role emphasizes collaboration, accuracy, and learning within a highly experienced Analytical Development team, contributing to NDA/MAA submissions and regulatory readiness.
Does it excite you to work with late-stage analytical development of innovative peptide-based medicines, and do you have a background in analytical science? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague.
As Analytical Scientist on a 12-month maternity cover, you will support late-stage analytical development across Development and Life Cycle Management (LCM) projects. You will be guided by experienced colleagues and gain hands-on experience in analytical work and in collaboration with Contract Development and Manufacturing Organizations (CDMOs).
We are looking for someone with an analytical mindset who is curious, careful, and eager to learn. You take ownership of your tasks, ask questions when needed, and enjoy working together with others.
You will join a highly experienced team in Analytical Development, where you will learn from colleagues who share their knowledge. We value a collaborative and supportive atmosphere in which great results are achieved together.
Let's bond and be bold.
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.
For further information, please contact Director, Head of Analytical Development, Iben Almar Meier; imeier@zealandpharma.com.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development.
The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts.
Learn more at www.zealandpharma.com.
Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes.
In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long-standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high-profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co-development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.